Takeda and existing investor Allianz X took part in a series C round closed in the wake of heightened demand for Amwell's telehealth technology platform.

Asahi Kasei Medical contributed to a round that took the total raised by the microbial detection technology provider past $255m.

Pfizer, Lundbeckfonden Ventures and Biomed Ventures have all taken part in a round for the anti-infective therapy developer that has now passed $90m.

The online teaching service was valued at $800m in a Fidelity-led round, adding to earlier funding from investors such as Bloomberg Beta, WME Ventures and Novel TMT.

The corporate-backed health management service raised the cash from Perceptive Advisors and has used $30m to buy musculoskeletal-focused Physera.

Edtech venture studio Entangled has been bought by Salesforce and Workday-backed Guild Education in an all-share deal sized above $80m.

Existing investors Cavallo Ventures and Syngenta Ventures returned to reinvest in the crop production technology developer’s series C round.

GV and Illumina Ventures returned to reinvest in cellular therapy developer SQZ Biotechnologies, an MIT spinout that has now raised at least $166m to date.

The oncology therapeutics developer, a spinoff from Spirogen, has increased the size of its initial public offering from almost $233m to nearly $268m.

SoftBank Vision Fund has invested $200m in the construction services provider, which announced the round at the same time as chief operating officer Paal Kibsgaard's ascendancy to CEO.